Here we overview the glucose-lowering and weight-reducing effects of incretin-based therapies, discussing the effective and safety use of DPP-4 inhibitors, GLP-1 RAs, and GIP/GLP-1 receptor agonist tripeptide in Japanese individuals with type 2 diabetes. Here, GIP is linked to type 2 diabetes mellitus.